Yohannes Ghebre (Baylor College of Medicine, Houston, TX, US) discusses the rationale and clinical evidence to date for using proton pump inhibitors (PPIs) to treat idiopathic pulmonary fibrosis (IPF).
1. What are the limitations of the currently approved drugs, pirfenidone and nintedanib, in idiopathic pulmonary fibrosis (IPF)? (0:11)
2. What is the rationale for using proton pump inhibitors (PPIs) to treat IPF? (1:08)
3. What clinical evidence exists for the use of PPIs in IPF? (2:06)
4. What (if any) are the potential safety issues in using PPIs to treat patients with IPF? (2:55)
5. What further studies are needed? (3:26)
Speaker disclosure: Yohannes Ghebre is an inventor on a patent, owned by Stanford University, that protects the use of proton pump inhibitors (PPIs) for the treatment of idiopathic pulmonary fibrosis (IPF).
Filmed at the American Thoracic Society (ATS) International Conference 2018, San Diego, CA, US, May 2018.
Related Videos In Interstitial Lung Disease
Lauren Troy, ERS 2019 – Transbronchial Lung Cryobiopsy for Interstitial Lung Disease Diagnosis
We met with Lauren Troy, from Royal Prince Alfred Hospital, Sydney, Australia at ERS 2019 in Madrid to discuss result of the COLDICE study into transbronchial lung cryobiopsy for interstitial lung disease diagnosis. Questions 1. In what clinical situation is a lung biopsy required to confirm a diagnosis of interstitial lung disease? (0:05) 2. What […]
Toby Maher, ERS 2019 – Pirfenidone in Patients with Progressive Fibrosing Unclassifiable ILD
Toby Maher, Royal Brompton Hospital, London, met with us at ERS 2019 in Madrid to discuss the results of a Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD (uILD). Questions 1. What is the definition of unclassifiable interstitial lung disease (uILD) and what proportion of ILD patients are considered unclassifiable? (0:05) […]
Mary E Strek, CHEST 2018 – Autoimmune lung diseases
Mary E Strek (University of Chicago, Chicago, IL, US) brings us up to speed on important aspects of autoimmune lung diseases. Questions 1. How prevalent are autoimmune lung diseases? (0:10) 2. What are the major autoimmune causes of interstitial lung diseases? (0:36) 3. What are the major challenges in the diagnosis and treatment of autoimmune […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!